Treatment of gustatory hyperlacrimation (crocodile tears) with injection of botulinum toxin into the lacrimal gland 
Introduction
Crocodile tear syndrome (CTS) or gustolacrimal reflex consists of unilateral lacrimation which occurs when a patient eats or drinks. [1] [2] [3] It was first described in 1913 and since then many cases have been reported in the medical literature. This rare phenomenon usually follows a Bell's palsy or a traumatic facial paralysis. It may occur congenitally with Duane's retraction syndrome. 4 The most commonly accepted mechanism for the pathogenesis of this abnormal reflex appears to be the misdirection of regenerating gustatory fibers from either the facial or glossopharyngeal nerves. After being injured the nerves may redirect themselves through the greater superficial petrosal nerve to reach the lacrimal gland, and cause ipsilateral tearing when the patient eats [1] [2] [3] ( Figure 1 ). An alternative hypothesis is that the nerve fibres do not actually regenerate, but rather form an artificial synapse at the site of the injury which allows the crossover of impulses from one fibre to another and interaction between afferent and efferent axons. 5 Many attempts have been made to abolish the annoying manifestations of this reflex. These include intraorbital injection of alcohol or cocaine to destroy postganglionic fibers of the sphenopalatine ganglion, subtotal resection of the lacrimal gland, sectioning of the glossopharyngeal and facial nerves at different levels and the use of anticholinergic drugs.
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The results have been extremely variable. Some of these treatments have resulted in total ablation of lacrimal secretion and some of threatened sight. Recent reports [6] [7] [8] suggest that injection of botulinum toxin type A (BTX-A) into the lacrimal gland of patients with CTS may effectively and safely abolish the reflex by chemodenervating the cholinergic neurons of the parasympathetic nervous system to the affected gland.
The purpose of this paper is to describe our initial experience with botulinum toxin to treat crocodile tear syndrome, to establish the efficacy and safety of the treatment and record possible complications.
Methods
Four patients with CTS were identified and included in the study after informed consent was obtained. Their ages ranged from 35 to 75 (mean of 57 years). Three had developed symptoms of gustatory hyperlacrimation following an episode of idiopathic facial paralysis more than a year earlier (range 1-4 years). The fourth developed symptoms following an ear infection 8 years previously. None of the patients was affected by involuntary synkinesia of the facial muscles or gustatory sweating. The demographic data of the patients, including the main clinical features, are shown in Table 1 .
Patients were asked to complete a questionnaire with numeric analog scales to assess the frequency and severity of the symptoms. A complete ophthalmic examination was performed which included measurements and description of the lid position, blink reflex, corneal sensation, quality of the corneal epithelial surface and tear break-up time. Tear secretion was documented by Schirmer's test. The patients were then given a sweet-sour candy to stimulate the gustatory reflex (Sherbet Lemons, Bassett's Fundays) and Schirmer's test was repeated. Treatment initially consisted of injecting 10 U of BTX-A into the lacrimal gland of the affected side via a transcutaneous route. Five hundred units of lyophilised botulinum toxin type A (Dysport  , Ipsen Ltd, Berks, UK) were reconstituted in 2.5 ml of 0.9% NaCl. The patients were asked to look inferonasally away from the affected lacrimal gland. The injection site was identified inferior to the superior orbital rim, at the junction between the lateral and medial third of the orbital rim. Ten units of botulinum toxin were injected slowly to a depth of 4-5 mm with a 30-gauge needle, bevel pointing away from the levator muscle ( Figure  2 ).
Patient 1 requested further treatment after 3.5 months when the effect of BTX-A wore off. He had initially developed a small ptosis after the first treatment and therefore to deliver the toxin more directly and reduce the chance of inducing further ptosis, this further injection of toxin was delivered transconjunctivally to the palpebral lobe of the lacrimal gland. Topical anaesthetic was applied, the lid double everted and gentle pressure applied at the lateral canthal area to expose the lacrimal gland. The gland was then injected under direct vision ( Figure 3 ). The fourth patient, who was recruited into the study at a Eye later date than the other patients, was also treated transconjunctivally as we felt that injection under direct vision was more accurate and potentially carried less risk of side effects. All patients were reviewed at 1 week, 1 month, 3 months and 6 months after the initial injection. At each visit the severity and frequency of the symptoms, as well as a complete ophthalmic examination were recorded. Any complications were noted. Further injections were given at the request of the patient. Special care was taken to document the duration of the changes in the reflex lacrimation and any side effects.
Results
At 1 week follow-up none of the three patients who had 10 U of BTX-A injected subcutaneously reported an improvement in symptoms. Therefore all three were treated with a second injection of 10 U 1 week after the first treatment. Following this second injection, all patients reported an almost complete resolution of symptoms within 4 days. The fourth patient had relief of symptoms following injection of 10 U of BTX-A under direct vision using the transconjunctival method of injection. Table 2 summarizes the effect of treatment.
Prior to treatment a Schirmer's test under taste stimulation showed an increase in tear production on the affected side as would be expected. Following treatment with BTX-A, tear production whilst eating decreased progressively and reached levels comparable to those produced without the gustatory stimulus. Figure 4 shows the Schirmer's test results of the affected eye of the treated patients at the initial baseline visit and following treatment.
Patients 1 and 4 noticed a return of symptoms 3.5 months after the initial injections and were therefore given a further BTX-A injection transconjunctivally at this time. Patients 2 and 3 continued to be free of symptoms at the 6-month follow-up visit. There was no apparent relationship between the severity of symptoms, duration of symptoms or degree of facial weakness and the effect of the treatment. Figure 5 shows the change in severity of symptoms following the injection of BTX-A. All patients experienced some minor side effects. Patient 1, who already had a 1 mm difference in the position of the upper lids prior to treatment, developed a 2 mm ptosis on the treated side. This presented 3 days after the second injection of 10 U of BTX-A and lasted for 2.5 months. The lid position remained unaltered in this patient after 20 U of BTX-A were injected transconjunctivally into the lacrimal gland. Patients 2 and 4 complained of mild stinging and dryness of the treated eye even though the pretherapeutic Schirmer test was not suggestive of poor background tear production. These symptoms lasted approximately 2 months and were easily controlled with a supplement of artificial tears. Patient 3 did not develop any ocular complications apart from an occasional conscious awareness of the presence of the eye ('that the eye was there'). None of the patients experienced diplopia or systemic side effects and the blink reflex, corneal sensation, tear break up time, and corneal epithelium remained unchanged during the follow-up period.
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Discussion
BTX-A acts to block the release of acetycholine in the neuromuscular and cholinergic nerve junctions. Prior to its use in the treatment of CTS it has been used similarly in Frey's syndrome (gustatory sweating) to stop transmission of impulses along aberrant autonomic nerve fibres to the sweat glands. [10] [11] [12] The first reports describing the use of BTX-A in the treatment of gustatory hyperlacrimation appear in the literature in 1998. Boroojerdi et al 6 initially published two cases of patients who had reflex lacrimation treated in this way. He also reported a further four patients who had BTX-A injection into the orbicularis oculi for involuntary synkinesia and coincidentally noted an improvement of their coexistent symptoms of reflex hyperlacrimation. Four months later Hofmann 7 first presented two patients at the annual meeting of the ASOPRS who were successfully treated with injections of BTX-A. Reimann et al 8 also reported a single case of CTS following idiopathic facial nerve palsy successfully treated with transconjunctival injection of BTX-A into the lacrimal gland. In our study all patients experienced a significant decrease in gustatory hyperlacrimation after BTX-A was injected into the lacrimal gland. This was demonstrated by a measured reduction in tearing in response to a taste stimulus as measured by the Schirmer test, and by a reduction in the frequency and severity of symptoms as reported by the patients. We found the duration of effect to be the same as reported in other studies and slightly longer than the recovery of orbicularis function following BTX-A injection for blepharospasm. 13, 14 The difference in duration of symptoms between the two patient groups may be due to a difference in time taken for axonal nerve sprouting following BTX-A injection at different sites, although there are no specific studies looking at this.
The cases reported so far in the literature have not all used the same preparations of BTX-A, or used the same route of injection and it is important to appreciate this when reviewing the literature.* Hofmann 7 treated his patients with a transcutaneous injection of 15 U of BOTOX  without direct visualisation of the gland. Reiman et al 8 however obtained nearly a complete resolution of the CTS symptoms with only half that dose, using the transconjunctival route. Boroojerdi et al 6 used Dysport  injected transcutaneously. We obtained improvement in reflex hyperlacrimation with 20 U injected into the lacrimal gland, initially via a transcutaneous route but later progressing to a transconjunctival route with direct visualisation of the gland. We would recommend that older patients receive an initial dose of only 15 U to avoid inducing dry eye syndrome. For a greater effect further toxin can be injected later in a stepwise manner. We found the best method of injection to be transconjunctival, as did Reimann et al. 8 With this approach one can be more confident that the entire amount of BTX-A is delivered directly into the lacrimal gland. This may explain why Reimann et al 8 were able to treat their patients with half the dose of BOTOX  than that used by Hofmann. 7 In summary we conclude from our initial experience with the use of BTX-A that it is effective in treating gustatory hyperlacrimation when injected into the lacrimal gland. CTS is however a rare condition and *There are two commercially available preparations of BTX-A:
BOTOX
 which originated in the USA and Dysport  in the UK, both of which are available in the UK. There is no exact conversion factor between the two, but 1 U of BOTOX  is approximately equivalent to 3-6 U of Dysport  . Eye patients must be warned about possible side effects and followed closely during their course of treatment. Complications may be avoided by careful selection of dose of toxin and transconjunctival injection into the palpebral lobe of the lacrimal gland.
